AMI Announces Formation of Sidoris Biomedical to Advance the Commercialization of Devices Created from Proprietary Bioresorbable Metal

Monday, April 24, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, April 24, 2017 /PRNewswire/ -- AMI (Advancing Medical Innovation LLC), a company dedicated to fostering the advancement

of medical technologies and products through partnerships between start-ups and industry leading medical manufacturers, has announced the formation of Sidoris Biomedical. The new company, funded by AMI, will focus exclusively on helping companies gain
access to medical devices created from a proprietary bioresorbable metal. This next generation metal technology is the result of focused research and development by BioDG, Inc., an organization with extensive experience in applying bioresorbable metal science to address significant clinical challenges.

To fuel the new company, Sidoris Biomedical has licensed the exclusive rights from BioDG for incorporating its bioresorbable metal technology in applications including: internal and external surgical stapling, surgical mesh and fixation, and ligation. The terms of the agreement were not disclosed.

Warren Pelissier, a partner with AMI and Sidoris stated, "Sidoris will be a tremendous springboard for introducing a new generation of medical devices. Our goal is to clinically advance revolutionary bioresorbable products and then enable companies within the market to purchase exclusive rights or licensing agreements. Sidoris represents a way for medical device companies to keep their product offering on the cutting edge while answering serious medical needs."

"Sidoris has extensive experience in the fields covered within this agreement," states Gordon Janko, CEO and Co-Founder of BioDG, Inc. "Our science is a game-changer. With our bio-materials, we can produce truly unique medical products that do their job and then go away. The technology has far-reaching implications as it can be applied to so many additional implantable applications. As a result, we are in active licensing discussions with a number of industry-leading companies."

Last year, BioDG licensed the exclusive rights of their bioresorbable metal for peripheral vascular stenting applications to one of the market-leading peripheral vascular stenting companies.

For more information about Sidoris Biomedical or available licensing agreements, please contact Warren Pelissier at AMI (email: [email protected], or call: 781.749.9290).

About AMIAdvancing Medical Innovation, Inc. was formed to help start-up companies with young technologies establish proof of concept and demonstrate clinical value. The company plays an active role in selling and licensing innovations to industry partners.

About BioDGBioDG, Inc. has pioneered bioresorbable metal technology that can be customized to meet specific clinical challenges. The company's bioresorbable metals are engineered to provide the necessary structural support for the required clinical duration and then gradually dissolve safely over time.

About SidorisSidoris Biomedical LLC provides healthcare industry leading companies access to next generation products that harness BioDG's proprietary bioresorbable metal technology.

Contact:AMI Warren Pelissier, [email protected]781.749.9290

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ami-announces-formation-of-sidoris-biomedical-to-advance-the-commercialization-of-devices-created-from-proprietary-bioresorbable-metal-300443361.html

SOURCE AMI



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store